High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib

J.L. Kuiper; D.A.M. Heideman; E. Thunnissen; A.W. van Wijk; P.E. Postmus; E.F. Smit

doi:https://doi.org/10.1016/j.ejca.2014.02.005

High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib

J.L. Kuiper, D.A.M. Heideman, E. Thunnissen, A.W. van Wijk, P.E. Postmus, E.F. Smit

Research output: Contribution to journal › Article › Academic › peer-review

7 Citations (Scopus)

Original language	English
Pages (from-to)	1399-401
Number of pages	3
Journal	European Journal of Cancer
Volume	50
Issue number	7
DOIs	https://doi.org/10.1016/j.ejca.2014.02.005
Publication status	Published - May 2014

Keywords

Antineoplastic Agents/administration & dosage
Carcinoma, Non-Small-Cell Lung/drug therapy
Disease Progression
ErbB Receptors/genetics
Erlotinib Hydrochloride
Humans
Lung Neoplasms/drug therapy
Meningeal Neoplasms/drug therapy
Protein Kinase Inhibitors/administration & dosage
Quinazolines/administration & dosage

Access to Document

https://doi.org/10.1016/j.ejca.2014.02.005

Cite this

Kuiper, J. L., Heideman, D. A. M., Thunnissen, E., van Wijk, A. W., Postmus, P. E., & Smit, E. F. (2014). High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib. European Journal of Cancer, 50(7), 1399-401. https://doi.org/10.1016/j.ejca.2014.02.005

@article{fcf3432c0dc646a7985ef20fb763a7ca,

title = "High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib",

keywords = "Antineoplastic Agents/administration & dosage, Carcinoma, Non-Small-Cell Lung/drug therapy, Disease Progression, ErbB Receptors/genetics, Erlotinib Hydrochloride, Humans, Lung Neoplasms/drug therapy, Meningeal Neoplasms/drug therapy, Protein Kinase Inhibitors/administration & dosage, Quinazolines/administration & dosage",

author = "J.L. Kuiper and D.A.M. Heideman and E. Thunnissen and {van Wijk}, A.W. and P.E. Postmus and E.F. Smit",

year = "2014",

month = may,

doi = "https://doi.org/10.1016/j.ejca.2014.02.005",

language = "English",

volume = "50",

pages = "1399--401",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

number = "7",

}

Kuiper, JL, Heideman, DAM, Thunnissen, E, van Wijk, AW, Postmus, PE & Smit, EF 2014, 'High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib', European Journal of Cancer, vol. 50, no. 7, pp. 1399-401. https://doi.org/10.1016/j.ejca.2014.02.005

High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib. / Kuiper, J.L.; Heideman, D.A.M.; Thunnissen, E. et al.
In: European Journal of Cancer, Vol. 50, No. 7, 05.2014, p. 1399-401.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib

AU - Kuiper, J.L.

AU - Heideman, D.A.M.

AU - Thunnissen, E.

AU - van Wijk, A.W.

AU - Postmus, P.E.

AU - Smit, E.F.

PY - 2014/5

Y1 - 2014/5

KW - Antineoplastic Agents/administration & dosage

KW - Carcinoma, Non-Small-Cell Lung/drug therapy

KW - Disease Progression

KW - ErbB Receptors/genetics

KW - Erlotinib Hydrochloride

KW - Humans

KW - Lung Neoplasms/drug therapy

KW - Meningeal Neoplasms/drug therapy

KW - Protein Kinase Inhibitors/administration & dosage

KW - Quinazolines/administration & dosage

U2 - https://doi.org/10.1016/j.ejca.2014.02.005

DO - https://doi.org/10.1016/j.ejca.2014.02.005

M3 - Article

C2 - 24582911

SN - 0959-8049

VL - 50

SP - 1399

EP - 1401

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 7

ER -